Vanguard Group Inc Scynexis Inc Transaction History

Vanguard Group Inc

$5.12 Trillion
Q2 2024

A detailed history of Vanguard Group Inc transactions in Scynexis Inc stock. As of the latest transaction made, Vanguard Group Inc holds 1,687,670 shares of SCYX stock, worth $2.28 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,687,670

Previous 1,687,670 -0.0%

Holding current value

$2.28 Million

Previous $2.48 Million 36.09%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$1.39 - $2.21 $179,522 - $285,428	129,153 Added 8.29%	1,687,670 $2.48 Million
Q4 2023 Feb 14, 2024	BUY	$1.56 - $2.24 $109,332 - $156,990	70,085 Added 4.71%	1,558,517 $3.48 Million
Q3 2023 Nov 14, 2023	BUY	$1.93 - $3.64 $41,699 - $78,645	21,606 Added 1.47%	1,488,432 $3.39 Million
Q2 2023 Aug 14, 2023	BUY	$2.38 - $3.67 $169,548 - $261,447	71,239 Added 5.1%	1,466,826 $4.33 Million
Q1 2023 May 15, 2023	BUY	$1.15 - $3.0 $83,933 - $218,958	72,986 Added 5.52%	1,395,587 $4.19 Million
Q4 2022 Feb 10, 2023	BUY	$1.46 - $2.94 $916 - $1,846	628 Added 0.05%	1,322,601 $2.06 Million
Q3 2022 Nov 14, 2022	BUY	$1.83 - $2.93 $523,076 - $837,493	285,834 Added 27.59%	1,321,973 $3.17 Million
Q2 2022 Aug 12, 2022	BUY	$1.77 - $3.87 $98,560 - $215,497	55,684 Added 5.68%	1,036,139 $1.93 Million
Q1 2022 May 13, 2022	SELL	$3.56 - $6.66 $11,406 - $21,338	-3,204 Reduced 0.33%	980,455 $3.83 Million
Q4 2021 Feb 14, 2022	BUY	$4.94 - $7.69 $541,690 - $843,239	109,654 Added 12.55%	983,659 $6 Million
Q3 2021 Nov 12, 2021	BUY	$5.3 - $7.89 $6,169 - $9,183	1,164 Added 0.13%	874,005 $4.63 Million
Q2 2021 Aug 13, 2021	BUY	$6.5 - $9.97 $5.67 Million - $8.7 Million	872,841 New	872,841 $6.42 Million

Others Institutions Holding SCYX

# of Institutions

Shares Held

14.4M

Call Options Held

34K

Put Options Held

View Full List

About SCYNEXIS INC

Ticker SCYX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 32,651,800
Market Cap $44.1M
Description
SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of vario...

More about SCYX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Account

Vanguard Group Inc Scynexis Inc Transaction History